Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.63 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | PGD | P52209 | 3/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709491 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL28125367 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL328992 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL34088 | 1.00 | MPI (0.63) | MPIPGK1PGK2PGDAKR1B1 | |
| Ammonia Solution, Strong SCHEMBL28280469 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| Phosphoric Acid SCHEMBL17103808 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| Phosphoric Acid SCHEMBL6754811 | 0.98 | MPI (0.61) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL18341376 | 0.92 | MPI (0.55) | MPIPGK1PGK2PGDAKR1B1 | |
| SCHEMBL10794963 | 0.92 | AKR1B1 (0.56) | MPIPGK1PGK2PGDAKR1B1 | |
| Methoxyamine SCHEMBL1703214 | 0.90 | MPI (0.53) | MPIPGK1PGK2PGDLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679065-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | California Institute of Technology (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019051001-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-3347718-A1 | MEASUREMENT OF MOLECULAR FLUX RATES BY QUANTIFYING ISOTOPOLOGUE ABUNDANCES USING HIGH RESOLUTION MASS SPECTROMETRY | KINEMED, INC. (US) | 2018-07-18 | — | — | EP | disclosed |
| CN-103842495-B | Glycerol fermentation is organic acid | 麦兰特公司 | 2018-04-13 | — | — | CN | disclosed |
| WO-2017044500-A1 | MEASUREMENT OF MOLECULAR FLUX RATES BY QUANTIFYING ISOTOPOLOGUE ABUNDANCES USING HIGH RESOLUTION MASS SPECTROMETRY | HELLERSTEIN MARC K (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-2288923-A2 | COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONEURON DISEASES | Kinemed, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009143365-A2 | COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONEURON DISEASES | KINEMED, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1759326-A4 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | UNIV CALIFORNIA (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1949085-A2 | MICROTUBULE SYNTHESIS AS A BIOMARKER | Kinemed, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007041611-A2 | MICROTUBULE SYNTHESIS AS A BIOMARKER | KINEMED, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006044045-A2 | CRYPTOSPORIDIUM HOMINIS GENES AND GENE PRODUCTS FOR CHEMOTHERAPEUTIC, IMMUNOPROPHYLACTIC AND DIAGNOSTIC APPLICATIONS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005098024-A1 | IN VIVO MEASUREMENT OF THE RELATIVE FLUXES THROUGH RIBONUCLEOTIDE REDUCTASE VS. DEOXYRIBONUCLEOSIDE PATHWAYS USING ISOTOPES | KINEMED, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005094327-A2 | ISOLATION OF EPITHELIAL CELLS OR THEIR BIOCHEMICAL CONTENTS FROM EXCRETA AFTER IN VIVO ISOTOPIC LABELING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005081943-A2 | MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMARKERS OF DRUG ACTION AND DISEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005051434-A1 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005015155-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009597-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1437966-A1 | MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER | The Regents of the University of California (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003061479-A1 | MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | disclosed |
| US-4278761-A | IMMOBILIZED ENZYMES, OXIDOREDUCTASE OR GLYCOLYTIC ENZYME PAIR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1981-07-14 | — | — | US | disclosed |